Daptomycin and tigecycline: A review of clinical efficacy in the antimicrobial era

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 14, 2007, Pages 2279-2292

  Ziglam, Hisham ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Antimicrobial resistance; Daptomycin; Resistant Gram negative; Resistant Gram positive; Tigecycline

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFTOBIPROLE; CEFTRIAXONE; CIPROFLOXACIN; CLOXACILLIN; DALBAVANCIN; DAPTOMYCIN; ERTAPENEM; FLUCLOXACILLIN; GENTAMICIN; GLYCYLCYCLINE DERIVATIVE; HABEKACIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICLAPRIM; LINEZOLID; NAFCILLIN; ORITAVANCIN; OXACILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOGRAMIN DERIVATIVE; TELITHROMYCIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ACIDOSIS; ACUTE PANCREATITIS; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BRAIN PSEUDOTUMOR; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG WITHDRAWAL; DYSPNEA; GRAM POSITIVE BACTERIUM; HUMAN; HYPERPHOSPHATEMIA; HYPOTENSION; IN VITRO STUDY; LIVER FUNCTION TEST; LOADING DRUG DOSE; LOEFFLER PNEUMONIA; MINIMUM INHIBITORY CONCENTRATION; MUSCLE DISEASE; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; NONHUMAN; PHARMACODYNAMICS; PHOTOSENSITIVITY; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; TOOTH DISEASE; UNITED STATES; UREA NITROGEN BLOOD LEVEL; UREMIA; URINARY TRACT INFECTION; VOMITING;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CARDIOVASCULAR INFECTIONS; DAPTOMYCIN; HUMANS; MINOCYCLINE;

EID: 35548968026     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.14.2279     Document Type: Review

References (81)

1. EDMOND MB, WALLACE SE, MCCLISH DK et al.: Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. (1999) 29(2):239-244.
2. NATHWANI D, BARLOW GD, AJDUKIEWICZ K et al.: Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy. J. Antimicrob. Chemother. (2003) 51(2):391-396.
3. BIEDENBACH DJ, MOET GJ, JONES RN: Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997 - 2002). Diagn. Microbiol. Infect. Dis. (2004) 50(1):59-69.
4. DIEKEMA DJ, PFALLER MA, SCHMITZ FJ et al.: Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997 - 1999. Clin. Infect. Dis. (2001) 32(Suppl. 2):S114-S132.
5. BARRETT JF: Recent developments in glycopeptide antibacterials. Curr. Opin. Investig. Drugs (2005) 6(8):781-790.
6. MENICHETTI F: Current and emerging serious Gram-positive infections. Clin. Microbiol. Infect. (2005) 11(Suppl. 3):22-28.
7. PLOWMAN R: The socioeconomic burden of hospital acquired infection. Euro Surveill. (2000) 5(4):49-50.
8. TALLY FP, ZECKEL M, WASILEWSKI MM et al.: Daptomycin: a novel agent for Gram-positive infections. Expert Opin. Investig. Drugs (1999) 8(8):1223-1238.
9. CARPENTER CF, CHAMBERS HF: Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin. Infect. Dis. (2004) 38(7):994-1000.
10. SILVERMAN JA, PERLMUTTER NG, SHAPIRO HM: Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. (2003) 47(8):2538-2544.
11. LAPLANTE KL, RYBAK MJ: Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. (2004) 48(12):4665-4672.
12. CLSI: Clinical and Laboratory Standards Institute. M7-A7, methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In: Approved Standard, 7th Edition, Wayne, PA7 CLSI (2006).
13. CLSI: Clinical and Laboratory Standards Institute. M100-S16, Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement. Wayne, PA7 CLSI (2006).
14. PFALLER MA, SADER HS, JONES RN: Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002 - 2005). Diagn. Microbiol. Infect. Dis. (2007)
15. SADER HS, STREIT JM, FRITSCHE TR, JONES RN: Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002 - 2004). Clin. Microbiol. Infect. (2006) 12(9):844-852.
16. WOODFORD N: Novel agents for the treatment of resistant Gram-positive infections. Expert Opin. Investig. Drugs (2003) 12(2):117-137.
17. RAAD I, HANNA H, JIANG Y et al.: Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob. Agents Chemother. (2007) 51(5):1656-1660.
18. GREEN MR, ANASETTI C, SANDIN RL, ROLFE NE, GREENE JN: Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. J. Oncol. Pharm. Pract. (2006) 12(3):179-181.
19. LEWIS JS II, OWENS A, CADENA J et al.: Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob. Agents Chemother. (2005) 49(4):1664-1665.
20. MARTY FM, YEH WW, WENNERSTEN CB et al.: Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J. Clin. Microbiol. (2006) 44(2):595-597.
21. SKIEST DJ: Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J. Clin. Microbiol. (2006) 44(2):655-656.
22. HAYDEN MK, REZAI K, HAYES RA et al.: Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. (2005) 43(10):5285-5287.
23. MANGILI A, BICA I, SNYDMAN DR, HAMER DH: Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. (2005) 40(7): 1058-1060.
24. SILVERMAN JA, OLIVER N, ANDREW T, LI T: Resistance studies with daptomycin. Antimicrob. Agents Chemother. (2001) 45(6):1799-1802.
25. CUI L, TOMINAGA E, NEOH HM, HIRAMATSU K: Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. (2006) 50(3):1079-1082.
26. AKINS RL, RYBAK MJ: In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob. Agents Chemother. (2000) 44(7):1925-1929.
27. CREDITO K, LIN G, APPELBAUM PC: Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus by time-kill methodology. Antimicrob. Agents Chemother. (2007).
28. RAND KH, HOUCK H: Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J. Antimicrob. Chemother. (2004) 53(3):530-532.
29. RAND KH, HOUCK HJ: Synergy of daptomycin with oxacillin and other β-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. (2004) 48(8):2871-2875.
30. DVORCHIK BH, BRAZIER D, DEBRUIN MF, ARBEIT RD: Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. (2003) 47(4):1318-1323.
31. LEE BL, SACHDEVA M, CHAMBERS HF: Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob. Agents Chemother. (1991) 35(12):2505-2508.
32. TALLY FP, DEBRUIN MF: Development of daptomycin for gram-positive infections. J. Antimicrob. Chemother. (2000) 46(4):523-526.
33. TEDESCO KL, RYBAK MJ: Daptomycin. Pharmacotherapy (2004) 24(1):41-57.
34. FUCHS PC, BARRYAL, BROWN SD: In vitro bactericidal activity of daptomycin against staphylococci. J. Antimicrob. Chemother. (2002) 49(3):467-470.
35. RYBAK MJ, HERSHBERGER E, MOLDOVAN T, GRUCZ RG: In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob. Agents Chemother. (2000) 44(4):1062-1066.
36. BUSH LM, BOSCIA JA, WENDELER M, PITSAKIS PG, KAYE D: In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob. Agents Chemother. (1989) 33(8):1198-1200.
37. 2+ and albumin on these drugs. Antimicrob. Agents Chemother. (1991) 35(9):1710-1716.
38. PETTI CA, FOWLER VG JR: Staphylococcus aureus bacteremia and endocarditis. Cardiol. Clin. (2003) 21(2):VII219-233.
39. FOWLER VG Jr, KONG LK, COREY GR et al.: Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J. Inject. Dis. (1999) 179(5):1157-1161.
40. WOODS CW, CHENG AC, FOWLER VG Jr et al.: Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin. Clin. Infect. Dis. (2004) 38(8):1188-1191.
41. CANTONI L, GLAUSER MP, BILLE J: Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob. Agents Chemother. (1990) 34(12):2348-2353.
42. CARON F, KITZIS MD, GUTMANN L et al.: Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob. Agents Chemother. (1992) 36(12):2611-2616.
43. FOWLER VG Jr, BOUCHER HW, COREY GR et al.: Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. (2006) 355(7):653-665.
44. SEGRETI JA, CRANK CW, FINNEY MS: Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy (2006) 26(3):347-352.
45. POUTSIAKA DD, SKIFFINGTON S, MILLER KB, HADLEY S, SNYDMAN DR: Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J. Infect. (2006) 54(6):567-571.
46. ARBEIT RD, MAKI D, TALLY FP, CAMPANARO E, EISENSTEIN BI: The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. (2004) 38(12):1673-1681.
47. PHARMACEUTICALS C: Data on file. Lexington, MA (2003).
48. SILVERMAN JA, MORTIN LI, VANPRAAGH AD, LI T, ALDER J: Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J. Infect. Dis. (2005) 191(12):2149-2152.
49. NABER KG EB, TALLY, FRANCIS P: Daptomycin versus ciprofloxacin in the treatment of complicated urinary tract infection due to gram-positive bacteria. Infect. Dis. Clin. Pract. (2004) 12(6):322-327.
50. CUBIST PHARMACEUTICALS: Data on file. In: Lexington, MA (2003).
51. HAYES D Jr, ANSTEAD MI, KUHN RJ: Eosinophilic pneumonia induced by daptomycin. J. Infect. (2007) 54(4):E211-E213.
52. BERGERON J, AMMIRATI M, DANLEY D et al.: Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob. Agents Chemother. (1996) 40(9):2226-2228.
53. FRITSCHE TR, SADER HS, STILWELL MG, DOWZICKY MJ, JONES RN: Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000 - 2004). Diagn. Microbiol. Infect. Dis. (2005) 52(3):195-201.
54. FRITSCHE TR, SADER HS, STILWELL MG, DOWZICKY MJ, JONES RN: Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn. Microbiol. Infect. Dis. (2005) 52(3):187-193.
55. SADER HS, JONES RN, STILWELL MG, DOWZICKY MJ, FRITSCHE TR: Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn. Microbiol. Infect. Dis. (2005) 52(3):181-186.
56. HOBAN DJ, BOUCHILLON SK, JOHNSON BM, JOHNSON JL, DOWZICKY MJ: In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program 2004). Diagn. Microbiol. Infect. Dis. (2005) 52(3):215-227.
57. SADER HS, JONES RN, DOWZICKY MJ, FRITSCHE TR: Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn. Microbiol. Infect. Dis. (2005) 52(3):203-208.
58. BRADFORD PA, WEAVER-SANDS DT, PETERSEN PJ: In vitro activity of tigecycline against isolates from patients enrolled in Phase III clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin. Infect. Dis. (2005) 41(Suppl. 5):S315-S332.
59. BOUCHILLON SK, HOBAN DJ, JOHNSON BM et al.: In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program 2004). Diagn. Microbiol. Infect. Dis. (2005) 52(3):173-179.
60. BIEDENBACH DJ, BEACH ML, JONES RN: In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases. Diagn. Microbiol. Infect. Dis. (2001) 40(4):173-177.
61. HOPE R, WARNER M, POTZ NA et al.: Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England. J. Antimicrob. Chemother. (2006) 58(6):1312-1314.
62. SCHEETZ MH, QI C, WARREN JR et al.: In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. (2007) 51(5):1621-1626.
63. WALLACE RJ Jr, BROWN-ELLIOTT BA, CRIST CJ, MANN L, WILSON RW: Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob. Agents Chemother. (2002) 46(10):3164-3167.
64. MURALIDHARAN G, MICALIZZI M, SPETH J, RAIBLE D, TROY S: Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. (2005) 49(1):220-229.
65. HOFFMAN H HW, DEMAIO RA, JORDAN J, KANTROWITZ D, HARPER J, SPETH J: Metabolic disposition of [14C]tigecycline in human volunteers following intravenous infusion In: 2004 AAPS Annual Meeting and Exposition, American Association of Pharmaceutical Scientists. Baltimore, USA (7 - 11 November 2004).
66. PHILADELPHIA PWP: Tigecycline Phamacokinetics (data on file) (2006).
67. CHIN TF, LACH JL: Drug diffusion and bioavailability: tetracycline metallic chelation. Am. J. Hosp. Pharm. (1975) 32(6):625-629.
68. SUN HK, ONG CT, UMER A et al.: Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob. Agents Chemother. (2005) 49(4):1629-1632.
69. TROY SM MG, MICALIZZI M: The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936). In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. (Chicago) Washington, DC: American Society for Microbiology (2003).
70. FOMIN P BM, GRADAUSKAS AEAL: Tigecycline is efficaciousin the treatment of complicated intra-abdominal infections. Int. J. Surg. (2005) 3:35-47.
71. OLIVA ME, REKHA A, YELLIN A et al.: A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; Clinical Trials.gov Identifier: NCT00081744]. BMC Infect. Dis. (2005) 5:88.
72. BABINCHAK T, ELLIS-GROSSE E, DARTOIS N, ROSE GM, LOH E: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. (2005) 41(Suppl. 5):S354-S367.
73. POSTIER RG, GREEN SL, KLEIN SR, ELLIS-GROSSE EJ, LOH E: Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin. Ther. (2004) 26(5):704-714.
74. SACCHIDANAND S, PENN RL, EMBIL JM et al.: Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a Phase III, randomized, double-blind trial. Int. J. Infect. Dis. (2005) 9(5):251-261.
75. BREEDT J, TERAS J, GARDOVSKIS J et al.: Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind Phase III comparison study with vancomycin-aztreonam. Antimicrob. Agents Chemother. (2005) 49(11):4658-4666.
76. ELLIS-GROSSE EJ, BABINCHAK T, DARTOIS N, ROSE G, LOH E: The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind Phase III comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. (2005) 41(Suppl. 5):S341-S353.
77. MURALIDHARAN G, FRUNCILLO RJ, MICALIZZI M, RAIBLE DG, TROY SM: Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob. Agents Chemother. (2005) 49(4):1656-1659.
78. MEAGHER AK, AMBROSE PG, GRASELA TH, ELLIS-GROSSE EJ: The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin. Infect. Dis. (2005) 41(Suppl. 5):S333-S340.
79. WYETH PHARMACEUTICS: Tygacil (Tigecycline) for injection. Wyeth Pharmaceuticals, Inc., Philadelphia, PA (2006).
80. NATHWANI D: Economic impact and formulary positioning of linezolid: a new anti-Gram-positive antimicrobial J. Hosp. Infect. (2001) 49(Suppl. A):S33-S41.
81. JOHNSON AP, MUSHTAQ S, WARNER M, LIVERMORE DM: Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid. Int. J. Antimicrob. Agents (2004) 24(4):315-319.